General
Preferred name
ACRIVASTINE
Synonyms
BW825C ()
Semprex ()
Acrivastin ()
BW 825C ()
BW-825C ()
Benadryl Allgy Relief Plus Decongest ()
P&D ID
PD013982
CAS
87848-99-5
Tags
available
drug
Approved by
FDA
First approval
1994
Drug Status
approved
Drug indication
Allergic rhinitis
Antihistaminic
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
15
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
MedChem Express Bioactive Compound Library
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
28
Properties
(calculated by RDKit )
Molecular Weight
348.18
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
2
cLogP
4.02
TPSA
53.43
Fraction CSP3
0.27
Chiral centers
0.0
Largest ring
6.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Immunology/Inflammation
Neuronal Signaling
Target
H1 receptor
HRH1
Histamine Receptor
Indication
allergic rhinitis
MOA
Histamine Receptor antagonist
Therapeutic Class
Antiinflammatory Agents
Source data
